Serum proteomics of active tuberculosis patients and contacts reveals unique processes activated during Mycobacterium tuberculosis infection. [PDF]
, 2020 Tuberculosis (TB) is the most lethal infection among infectious diseases. The specific aim of this study was to establish panels of serum protein biomarkers representative of active TB patients and their household contacts who were either infected (LTBI)
Anibarro, L +11 more
core +2 more sources
The rise of companies from emerging markets in global health governance: opportunities and challenges [PDF]
, 2014 The article analyses the involvement of pharmaceutical companies from emerging markets in global health governance. It finds that they play a central role as low-cost suppliers of medicines and vaccines and, increasingly, new technologies.
ANNE ROEMER-MAHLER +23 more
core +1 more source
Mesoporous Silica Nanoparticles as a Potential Platform for Vaccine Development against Tuberculosis
Pharmaceutics, 2020 The increasing emergence of new strains of Mycobacterium tuberculosis (Mtb) highly resistant to antibiotics constitute a public health issue, since tuberculosis still constitutes the primary cause of death in the world due to bacterial infection. Mtb has
Sandra Montalvo-Quirós +6 more
doaj +1 more source
PLGA particulate subunit tuberculosis vaccines promote humoral and Th17 responses but do not enhance control of Mycobacterium tuberculosis infection. [PDF]
PLoS ONE, 2018 Tuberculosis places a staggering burden on human health globally. The new World Health Organisation End-TB Strategy has highlighted the urgent need for more effective TB vaccines to improve control of the disease.
Anneliese S Ashhurst +7 more
doaj +1 more source
Using Shewhart charts to monitor quality characteristics of preventive vaccines for tuberculosis
Биопрепараты: Профилактика, диагностика, лечение, 2023 Scientific relevance. The quality of medicinal products, particularly vaccines, is contingent on the stability of the manufacturing process at all stages, which can be evaluated using Shewhart charts for data obtained by monitoring the quality attributes
A. A. Savina +2 more
doaj +1 more source
Protection efficacy of Argentinian isolates of Mycobacterium avium subsp. paratuberculosis with different genotypes and virulence in a murine model [PDF]
, 2018 Paratuberculosis is a chronic disease caused by Mycobacterium avium subsp. paratuberculosis (Map). The disease causes economic losses and, therefore, it is imperative to follow proper control strategies, which should include an effective vaccine. Several
Alvarado Pinedo, María Fiorella +8 more
core +1 more source
Integrating fish models in tuberculosis vaccine development
Disease Models & Mechanisms, 2020 Tuberculosis is a chronic infection by Mycobacterium tuberculosis that results in over 1.5 million deaths worldwide each year. Currently, there is only one vaccine against tuberculosis, the Bacillus Calmette–Guérin (BCG) vaccine.
Anni K. Saralahti +3 more
doaj +1 more source
Mechanistic Modeling of Mycobacterium tuberculosis Infection in Murine Models for Drug and Vaccine Efficacy Studies. [PDF]
, 2020 Tuberculosis (TB) drug, regimen, and vaccine development rely heavily on preclinical animal experiments, and quantification of bacterial and immune response dynamics is essential for understanding drug and vaccine efficacy.
Nuermberger, Eric L +6 more
core +1 more source
Emerging respiratory viral infections: MERS-CoV and influenza [PDF]
, 2014 This article is made available for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source.
Al-Tawfiq, Jaffar A., Memish, Ziad A.
core +1 more source
Next-Generation TB Vaccines: Progress, Challenges, and Prospects
Vaccines, 2023 Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB), is a prevalent global infectious disease and a leading cause of mortality worldwide. Currently, the only available vaccine for TB prevention is Bacillus Calmette–Guérin (BCG).
Li Zhuang +4 more
doaj +1 more source